Consistent with previous reports, these data indicate that there is a subset of TRD patients with increased inflammatory markers, and this may be useful in prediction of treatment response.4, 10 We identified low levels of serum FGF-2 as a specific predictor of ketamine treatment response. This evidence concerns the gene FGF2 and treatment resistant depression.